Prime Therapeutics' leading research shows only 1 in 12 remain on a GLP-1 drug for obesity at three years News provided by Prime Therapeutics LLC Jun 25, 2025, 10:00 ET Findings also show improved persistence with high-potency, obesity-approved GLP-1 products EAGAN, Minn., June 25, 2025 /PRNewswire/ -- Only 8% of individuals (or 1 in 12) initiating a glucagon-like peptide-1 (GLP-1) agonist drug for obesity without diabetes continued to do so at three years, according to the latest real-world research from pharmacy solutions partner Prime Therapeutics LLC (Prime)
Disclaimer: This post is for educational purposes only and does not substitute for professional medical advice, diagnosis, or treatment
The manufacturing of sterile injectables adheres to strict regulatory standards and quality to protect patient health
Emotion: Acknowledge the emotional impact of hair loss but focus on your health goals and give yourself time to adjust
Contents Top Fiber Supplements for Women: Reviews and Comparisons Here are some of the most reliable and outstanding fiber supplement products on the market: ColonBroom ColonBroom is a revolutionary fiber supplement that has been transforming lives worldwide, especially for women, with its comprehensive approach to gut health and overall wellness